ADMP - Adamis Pharmaceuticals Corporation
2.94 +0.31 (11.79%)
Pre-Market: 7:42AM EST
| Previous Close | 2.5100 |
| Open | 2.5200 |
| Bid | 2.91 x 1000 |
| Ask | 2.97 x 1200 |
| Day's Range | 2.5000 - 2.6300 |
| 52 Week Range | 2.0100 - 5.1000 |
| Volume | 41,330 |
| Avg. Volume | 392,682 |
| Market Cap | 124.376M |
| Beta (3Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- MarketWatch•15 hours ago
Adamis stock surges on release of EpiPen alternative
Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the U.S., we worked together with Sandoz in getting this potentially life-saving quality product into the market as quickly as possible," said Dennis Carlo, chief executive at Adamis, in a statement.
- GlobeNewswire•15 hours ago
Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
Adamis Pharmaceuticals Corporation (ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz Inc. has significant experience and knowledge, followed by introduction into the retail market.
- GlobeNewswire•14 days ago
Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•15 days ago
Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James
Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) announced its NDA filing Friday for a fast-dissolving sublingual tadalafil tablet for erectile dysfunction. The Analyst Raymond James analyst Elliot Wilbur maintained ...
- GlobeNewswire•17 days ago
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe (PFS) product candidate. This injection is designed for the treatment of an opioid overdose. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
- ACCESSWIRE•17 days ago
4 Pharma Stocks Gaining Speed on Monday (12/31/18)
From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday. Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.
- GlobeNewswire•19 days ago
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet
Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its fast-dissolving sublingual tadalafil tablet. This product candidate is designed for the treatment of erectile dysfunction. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
- Zacks•27 days ago
Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks•last monthImplied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Reuters•last month
Novartis to launch Adamis' EpiPen rival in U.S. next year
Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.
- GlobeNewswire•last month
Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
Adamis Pharmaceuticals Corporation (ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc., a Novartis division, which has exclusive rights to market and distribute Symjepi in the U.S., to prepare for the U.S. market introduction of this life-saving treatment. Manufacture of commercial batches has been completed and Adamis will begin shipping to Sandoz distribution centers during December to ensure the appropriate supply for launch. SYMJEPI (epinephrine) 0.3mg Injection is indicated for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
- Zacks•2 months ago
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
- Zacks•2 months ago
Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
Adamis (ADMP) delivered earnings and revenue surprises of -40.00% and -28.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Adamis: 3Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
SAN DIEGO, Nov. 09, 2018 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business.
- Zacks•2 months ago
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•3 months ago
Could Adamis Pharmaceuticals Corporation’s (NASDAQ:ADMP) Investor Composition Impacts Your Returns?
A look at the shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...
- Zacks•4 months ago
Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
- ACCESSWIRE•4 months ago
Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and its Symjepi (epinephrine) Injection 0.15mg product is undergoing FDA review. ADMP has selected Novartis unit Sandoz to launch the product in the U.S. (the FDA approved the 0.30 mg version in November 2017).
- Zacks•4 months ago
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•4 months ago
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
Market Realist•5 months agoMylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
